Investors
Announcements 2019
Glenmark Pharmaceuticals announces product approval for Ryaltris(R) in Australia
Certificate of Compliance issued by the European regulator, SUKL, Czech Republic for Glenmark’s Baddi manufacturing facility
Newspaper Publication of Q2 FY 2019-20
Glenmark’s consolidated revenue rises 9.05% to Rs. 28,150.4 Mn. in Q2 FY 2019-20
Glenmark’s MDA Q2 FY 2019 – 20
Glenmark’s Q2 FY 2019-20 Results
Glenmark Pharmaceuticals receives ANDA approval for Adapalene and Benzoyl Peroxide Gel, 0.1%|2.5%
Q2 FY20 Earnings Concall Invitation - November 15, 2019
BM Notice Newspaper Publication – 14th November, 2019
Notice of Board Meeting - 14th November, 2019
Proceedings and Scrutinizer's Report of the 41st AGM
Newspaper Publication of Annual General Meeting Notice
Glenmark AGM Notice 2019
AGM Intimation to the Exchange
Glenmark Pharmaceuticals receives ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)
Glenmark’s consolidated revenue at Rs. 23,228.79 Mn. for Q1 FY 2019 – 20
Glenmark’s MDA Q1 FY 2019 – 20
Glenmark’s Q1 FY 2019-20 Results
Glenmark Q1 FY 2019 – 20 Results Earnings Call
BM Notice Newspaper Publication – 13th August, 2019
Notice of Board Meeting - 13th August, 2019
Credit Rating by Fitch Ratings
Newspaper Publication - Notice to Shareholder for transfer of shares to IEPF
FDA Issues Complete Response Letter for Ryaltris™ (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg])
Newspaper Publication of Q4 Results
Glenmark’s MDA Q4 FY 2018 – 19
Glenmark’s consolidated revenue rises 12.44% to Rs. 25,634.74 Mn. for Q4 FY 2018-19
Glenmark’s Q4 FY 2018-19 Results
BM Notice Newspaper Publication – 29th May, 2019
Glenmark Q4 FY 2018 - 19 Results Earnings Call
Board Meeting Intimation – 29th May, 2019
Newspaper Publication of Q3 Results
Glenmark’s consolidated revenue rises 15.95% to Rs. 25,550.45 Mn. in Q3 FY 2018 – 19
Glenmark’s MDA Q3 FY 2018 – 19
Glenmark’s Q3 FY 2018-19 Results
BM Newspaper Publication – 14th February, 2019
Glenmark Q3 FY 2018 - 19 Results Earnings Call
Board Meeting Intimation – 14th February, 2019
About Us
Leading, integrated, global, research-led organization. Words which define us and our vision to discover a healthier future